Inhibitex Regains Compliance with NASDAQ Listing Requirements
September 24 2009 - 11:45AM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a
biopharmaceutical company focused on developing products to treat
serious infectious diseases, announced today that it has received
notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the
closing bid price of the Company’s common stock has been at or
above $1.00 per share for 10 consecutive business days, the Company
has regained compliance with Nasdaq’s Listing Rule 5550(a)(2) and
its delisting matter has been closed. Accordingly, the Company is
currently in full compliance with all listing requirements of the
Nasdaq Capital Market.
For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024